Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
Amy Musiek, Kerri E. Rieger, M. Bagot, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 29-40
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
Johanna Latzka, Chalid Assaf, M. Bagot, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113343-113343
Open Access | Times Cited: 68
Clinicopathological definition, management and prognostic value of mogamulizumab‐associated rash and other cutaneous events: A systematic review
Gianluca Avallone, Gabriele Roccuzzo, Alessandro Pileri, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 9, pp. 1738-1748
Open Access | Times Cited: 12
Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study
M. Beylot‐Barry, G. Quéreux, Charlée Nardin, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1777-1784
Open Access | Times Cited: 22
Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review
M. Fernández‐Guarino, Pablo L. Ortiz‐Romero, Fernando Gallardo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2203-2203
Open Access | Times Cited: 6
Mogamulizumab‐associated rash – Case series and review of the literature
Inga Hansen, Finn Abeck, Anne Menz, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 8, pp. 1079-1086
Open Access | Times Cited: 4
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Francine M. Foss, Youn H. Kim, Julia Scarisbrick, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Exanthematische Arzneimittelreaktionen
Mirjana Ziemer, Elisabeth Livingstone
Deleted Journal (2025)
Closed Access
Praxisempfehlungen für die Therapie und Überwachung von Mogamulizumab‐Patienten in Deutschland
Chalid Assaf, Nina Booken, Edgar Dippel, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025) Vol. 23, Iss. 3, pp. 341-356
Open Access
Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome*
Marie Roelens, Adèle de Masson, Anaïs Andrillon, et al.
British Journal of Dermatology (2022) Vol. 186, Iss. 6, pp. 1010-1025
Closed Access | Times Cited: 18
Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases
Mathias Oymanns, Michael Daum-Marzian, Chalid Assaf
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5412-5421
Open Access | Times Cited: 2
Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
Laura Caruso, Alessia Castellino, Daniela Dessì, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 3205-3221
Open Access | Times Cited: 8
Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
Carine Lama, Miguel A. Hernandez‐Rovira, Neha Mehta‐Shah, et al.
JAAD Case Reports (2023) Vol. 38, pp. 64-67
Open Access | Times Cited: 4
Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events
Safiyyah Bhatti, Daniel Joffe, Lauren Banner, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 4
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report
J.-M. L’Orphelin
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 1
A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments
Corrado Zengarini, Alba Guglielmo, Martina Mussi, et al.
Antibodies (2024) Vol. 13, Iss. 2, pp. 32-32
Open Access | Times Cited: 1
Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib
Daniel Martín‐Torregrosa, Ignacio Torres‐Navarro, Miguel Mansilla‐Polo, et al.
JAMA Dermatology (2024)
Closed Access | Times Cited: 1
Mogamulizumab‐induced granulomatous dermatitis of the scalp: a distinct entity associated with clinical response
A. Pacaud, E. Criquet, A. Durlach, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 10
Closed Access | Times Cited: 7
Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides
Jingying Wang, C. Ram‐Wolff, Gábor Dobos, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 1, pp. 129-131
Closed Access | Times Cited: 6
Inflammatory arthritis complicating mogamulizumab treatment of Sézary syndrome
Anne R. Bass, M. Sama
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. e113-e114
Closed Access | Times Cited: 2
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
Benedetta Sonego, Adalberto Ibatici, Giulia Rivoli, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2656-2656
Open Access | Times Cited: 2
The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy
Riyad N. H. Seervai, Sarah Friske, Emily Y. Chu, et al.
Journal of Cutaneous Pathology (2022) Vol. 50, Iss. 1, pp. 72-95
Closed Access | Times Cited: 3
Immunobiology and treatment of cutaneous T-cell lymphoma
Rishi R. Goel, Alain H. Rook
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 8, pp. 985-996
Closed Access
Drug-related exanthema under immunotherapy and targeted oncological therapy
Mirjana Ziemer, Elisabeth Livingstone
Deleted Journal (2024) Vol. 75, Iss. 6, pp. 440-450
Closed Access
Mogamulizumab‐assoziierter Rash – Fallserie und aktuelle Literatur
Inga Hansen, Finn Abeck, Anne Menz, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 8, pp. 1079-1087
Closed Access
A case of mogamulizumab‐induced vitiligo in a patient with mycosis fungoides
Charissa Obeng-Nyarko, Ciara G. Robinson, Anna R. Axelson
JEADV Clinical Practice (2024) Vol. 3, Iss. 5, pp. 1705-1707
Open Access
Page 1 - Next Page

Scroll to top